Biotech Values

[DewDiligence]

They haven’t moved that far, possibly EMA relocation slowed down all of their initiatives.

Thanks. I presume that adopting the FDA’s method of recompiling datasets from individual-patient data would require the EMA to beef up central staffing. (The rapporteur review teams probably don’t have the expertise to perform this task.)